Maverick Capital Ltd. Grows Stock Holdings in Humana Inc. (NYSE:HUM)

Maverick Capital Ltd. grew its holdings in Humana Inc. (NYSE:HUM) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 197,892 shares of the insurance provider’s stock after acquiring an additional 6,322 shares during the period. Humana comprises 1.2% of Maverick Capital Ltd.’s holdings, making the stock its 27th biggest position. Maverick Capital Ltd.’s holdings in Humana were worth $62,680,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in HUM. FMR LLC raised its position in Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after acquiring an additional 643,291 shares during the period. Pzena Investment Management LLC raised its position in shares of Humana by 8.1% in the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after buying an additional 187,903 shares during the last quarter. Davis Selected Advisers grew its holdings in shares of Humana by 16.1% in the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after purchasing an additional 321,233 shares during the period. Marshall Wace LLP grew its holdings in shares of Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after purchasing an additional 774,085 shares during the period. Finally, Legal & General Group Plc grew its holdings in shares of Humana by 2.1% in the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after purchasing an additional 24,842 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of HUM opened at $296.78 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a market cap of $35.74 billion, a price-to-earnings ratio of 26.29, a PEG ratio of 2.34 and a beta of 0.52. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $504.79. The business’s 50 day moving average is $275.33 and its two-hundred day moving average is $329.47.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Analysts forecast that Humana Inc. will post 15.86 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.19%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is currently 31.36%.

Analyst Upgrades and Downgrades

HUM has been the subject of several research analyst reports. Leerink Partnrs lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Wells Fargo & Company lowered their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and raised their price objective for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. UBS Group lowered their price objective on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, October 4th. Finally, Royal Bank of Canada lowered their price objective on shares of Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Twenty analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.